Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria.
Lee EA, Palmer DR, Flanagan KL, Reece WH, Odhiambo K, Marsh K, Pinder M, Gravenor MB, Keitel WA, Kester KE, Diggs C, Kaslow D, Apostolopoulos V, Ballou WR, Hill AV, Krzych U, Plebanski M. Lee EA, et al. Among authors: kaslow d. Infect Immun. 2002 Mar;70(3):1417-21. doi: 10.1128/IAI.70.3.1417-1421.2002. Infect Immun. 2002. PMID: 11854228 Free PMC article. Clinical Trial.
A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, Andersen RF, Bejon P, Goonetilleke N, Poulton I, Webster DP, Butcher G, Watkins K, Sinden RE, Levine GL, Richie TL, Schneider J, Kaslow D, Gilbert SC, Carucci DJ, Hill AV. Dunachie SJ, et al. Among authors: kaslow d. Infect Immun. 2006 Oct;74(10):5933-42. doi: 10.1128/IAI.00590-06. Infect Immun. 2006. PMID: 16988273 Free PMC article. Clinical Trial.
Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.
Kumar S, Collins W, Egan A, Yadava A, Garraud O, Blackman MJ, Guevara Patino JA, Diggs C, Kaslow DC. Kumar S, et al. Among authors: kaslow dc. Infect Immun. 2000 Apr;68(4):2215-23. doi: 10.1128/IAI.68.4.2215-2223.2000. Infect Immun. 2000. PMID: 10722622 Free PMC article.
Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.
Keitel WA, Kester KE, Atmar RL, White AC, Bond NH, Holland CA, Krzych U, Palmer DR, Egan A, Diggs C, Ballou WR, Hall BF, Kaslow D. Keitel WA, et al. Among authors: kaslow d. Vaccine. 1999 Oct 14;18(5-6):531-9. doi: 10.1016/s0264-410x(99)00221-2. Vaccine. 1999. PMID: 10519944 Clinical Trial.
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.
Tine JA, Lanar DE, Smith DM, Wellde BT, Schultheiss P, Ware LA, Kauffman EB, Wirtz RA, De Taisne C, Hui GS, Chang SP, Church P, Hollingdale MR, Kaslow DC, Hoffman S, Guito KP, Ballou WR, Sadoff JC, Paoletti E. Tine JA, et al. Among authors: kaslow dc. Infect Immun. 1996 Sep;64(9):3833-44. doi: 10.1128/iai.64.9.3833-3844.1996. Infect Immun. 1996. PMID: 8751936 Free PMC article.
Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum.
Egan AF, Chappel JA, Burghaus PA, Morris JS, McBride JS, Holder AA, Kaslow DC, Riley EM. Egan AF, et al. Among authors: kaslow dc. Infect Immun. 1995 Feb;63(2):456-66. doi: 10.1128/iai.63.2.456-466.1995. Infect Immun. 1995. PMID: 7822010 Free PMC article.
Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.
Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Ballou WR, et al. Ockenhouse CF, et al. Among authors: kaslow dc. J Infect Dis. 1998 Jun;177(6):1664-73. doi: 10.1086/515331. J Infect Dis. 1998. PMID: 9607847 Clinical Trial.
Passive transfer of growth-inhibitory antibodies raised against yeast-expressed recombinant Plasmodium falciparum merozoite surface protein-1(19).
Gozalo A, Lucas C, Cachay M, Wellde BT, Hall T, Bell B, Wood J, Watts D, Wooster M, Lyon JA, Moch JK, Haynes JD, Williams JS, Holland C, Watson E, Kester KE, Kaslow DC, Ballou WR. Gozalo A, et al. Among authors: kaslow dc. Am J Trop Med Hyg. 1998 Dec;59(6):991-7. doi: 10.4269/ajtmh.1998.59.991. Am J Trop Med Hyg. 1998. PMID: 9886211
233 results